Analysis Article • May 01

Over the last 7 days, the Clinical Research and Equipment industry has risen 2.3%, driven by gains from AddLife of 3.1%. Meanwhile, Genovis AB (publ.) actually underperformed within the industry, shrinking 6.7% in the last week. In contrast, the industry has lost 13% in the last 12 months. As for the next few years, earnings are expected to grow by 19% per annum.
Has the Swedish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 28 May 2026 | SEK 30.0b | SEK 14.6b | -SEK 849,175,077.00 | 37.6x | -35.3x | 2.1x |
| Sat, 25 Apr 2026 | SEK 29.8b | SEK 14.6b | -SEK 971,664,077.00 | 34.5x | -30.7x | 2x |
| Mon, 23 Mar 2026 | SEK 26.3b | SEK 14.6b | -SEK 838,374,077.00 | 31.2x | -31.4x | 1.8x |
| Wed, 18 Feb 2026 | SEK 26.8b | SEK 14.9b | -SEK 553,301,427.00 | 32.3x | -48.3x | 1.8x |
| Fri, 16 Jan 2026 | SEK 30.0b | SEK 14.9b | -SEK 744,515,427.00 | 47.4x | -40.3x | 2x |
| Sun, 14 Dec 2025 | SEK 32.9b | SEK 14.9b | -SEK 744,515,427.00 | 54.5x | -44.2x | 2.2x |
| Tue, 11 Nov 2025 | SEK 34.7b | SEK 14.7b | -SEK 748,598,012.00 | 58.1x | -46.4x | 2.4x |
| Thu, 09 Oct 2025 | SEK 35.1b | SEK 14.7b | SEK 61.3m | 58.4x | 572.7x | 2.4x |
| Sat, 06 Sep 2025 | SEK 34.9b | SEK 14.7b | SEK 60.9m | 56.4x | 573.1x | 2.4x |
| Mon, 04 Aug 2025 | SEK 35.8b | SEK 14.8b | SEK 158.0m | 61.3x | 226.3x | 2.4x |
| Wed, 02 Jul 2025 | SEK 46.5b | SEK 16.6b | SEK 416.3m | 68.5x | 111.7x | 2.8x |
| Fri, 30 May 2025 | SEK 45.6b | SEK 16.6b | SEK 404.2m | 72.3x | 112.9x | 2.7x |
| Sun, 27 Apr 2025 | SEK 43.1b | SEK 16.6b | SEK 642.3m | 44.1x | 67.1x | 2.6x |
| Tue, 25 Mar 2025 | SEK 36.9b | SEK 16.6b | SEK 614.3m | 39x | 60.1x | 2.2x |
| Thu, 20 Feb 2025 | SEK 44.0b | SEK 17.0b | -SEK 1,033,505,426.00 | 43.3x | -42.6x | 2.6x |
| Sat, 18 Jan 2025 | SEK 39.1b | SEK 16.7b | -SEK 1,152,911,426.00 | 42.2x | -33.9x | 2.3x |
| Mon, 16 Dec 2024 | SEK 44.1b | SEK 16.7b | -SEK 1,152,911,426.00 | 50.4x | -38.3x | 2.6x |
| Wed, 13 Nov 2024 | SEK 44.2b | SEK 16.8b | -SEK 948,072,426.00 | 50.3x | -46.6x | 2.6x |
| Fri, 11 Oct 2024 | SEK 46.5b | SEK 16.7b | -SEK 988,175,491.00 | 57.2x | -47.1x | 2.8x |
| Sun, 08 Sep 2024 | SEK 47.4b | SEK 16.7b | -SEK 988,176,492.00 | 59.9x | -48x | 2.8x |
| Tue, 06 Aug 2024 | SEK 46.3b | SEK 16.7b | -SEK 1,128,120,510.00 | 58.2x | -41x | 2.8x |
| Thu, 04 Jul 2024 | SEK 42.2b | SEK 16.3b | -SEK 1,188,686,510.00 | 54.2x | -35.5x | 2.6x |
| Sat, 01 Jun 2024 | SEK 43.6b | SEK 16.3b | -SEK 1,188,686,510.00 | 62.9x | -36.7x | 2.7x |
| Mon, 29 Apr 2024 | SEK 37.7b | SEK 16.2b | -SEK 1,246,589,705.00 | 36.2x | -30.2x | 2.3x |
| Wed, 27 Mar 2024 | SEK 40.4b | SEK 16.0b | -SEK 1,122,792,210.00 | 34.6x | -36x | 2.5x |
| Fri, 23 Feb 2024 | SEK 39.3b | SEK 16.0b | -SEK 1,119,170,478.00 | 43x | -35.1x | 2.5x |
| Sun, 21 Jan 2024 | SEK 35.8b | SEK 15.5b | -SEK 1,393,723,683.00 | 42.9x | -25.7x | 2.3x |
| Tue, 19 Dec 2023 | SEK 38.2b | SEK 15.5b | -SEK 1,393,723,683.00 | 45.3x | -27.4x | 2.5x |
| Thu, 16 Nov 2023 | SEK 32.3b | SEK 15.4b | -SEK 1,256,647,710.00 | 36.3x | -25.7x | 2.1x |
| Sat, 14 Oct 2023 | SEK 24.0b | SEK 15.1b | -SEK 1,134,516,711.00 | 33.5x | -21.2x | 1.6x |
| Mon, 11 Sep 2023 | SEK 29.2b | SEK 15.1b | -SEK 1,133,713,072.00 | 38.8x | -25.8x | 1.9x |
| Wed, 09 Aug 2023 | SEK 31.8b | SEK 15.1b | -SEK 213,871,038.00 | 45.7x | -148.5x | 2.1x |
| Fri, 07 Jul 2023 | SEK 35.6b | SEK 14.6b | -SEK 172,476,038.00 | 39x | -206.2x | 2.4x |
| Sun, 04 Jun 2023 | SEK 40.0b | SEK 14.6b | -SEK 172,476,038.00 | 39.5x | -231.7x | 2.7x |
-231.7x
How does Swedish Clinical Research and Equipment compare with similar industries?
| SE Market | 2.86% | |
| Healthcare | 2.70% | |
| Life Sciences | 2.26% | |
| Clinical Research and Equipment | 2.26% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALIF B AddLife | SEK 150.40 | 0.3% +SEK 48.7m | -18.0% | PE32.3x | |
| BICO BICO Group | SEK 19.32 | 3.2% +SEK 42.3m | -45.1% | PS0.9x | |
| IDLDX IDL Diagnostics | SEK 0.49 | 16.1% +SEK 15.7m | -14.0% | PS2.1x | |
| ATANA Attana | SEK 0.007 | 16.7% +SEK 2.6m | -75.0% | PS4.5x | |
| LEVBIO Level Bio | SEK 0.31 | 10.6% +SEK 2.1m | -29.1% | PS0.6x |